Diarrhea

Disease-a-Month

Volumn 57, Issue 9, 2011, Pages 490-510

  Deepak, Parakkal ^a   Ehrenpreis, Eli D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALPHA GLUCOSIDASE INHIBITOR; ALVIMOPAN; ANTHRAQUINONE DERIVATIVE; ANTIBIOTIC AGENT; BETHANECHOL; CARBAMIC ACID DERIVATIVE; CASTOR OIL; CHENODEOXYCHOLIC ACID; CHOLINESTERASE INHIBITOR; CISAPRIDE; DIACEREIN; DIPHENYLMETHANE 4,4' DIISOCYANATE; DOCUSATE SODIUM; DOMPERIDONE; ERYTHROMYCIN; HUPERZINE A; IRINOTECAN; LACTULOSE; LAXATIVE; LUBIPROSTONE; METOCLOPRAMIDE; MISOPROSTOL; OMEPRAZOLE; PREBIOTIC AGENT; PROPRANOLOL; PRUCALOPRIDE; TEGASEROD; THEOPHYLLINE; UNINDEXED DRUG;

ANTICHOLINERGIC EFFECT; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; DIARRHEA; DRUG SAFETY; HARD FECES; HUMAN; INFECTIOUS DIARRHEA; LOOSE FECES; NEUROMUSCULAR DISEASE; NUTRITIONAL ASSESSMENT; OSMOSIS; PSEUDOMEMBRANOUS COLITIS; SODIUM ABSORPTION; STEATORRHEA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLITIS; COLON; COLONOSCOPY; DIARRHEA; DRUG THERAPY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL MOTILITY; HUMANS; MUSCLE CONTRACTION; SODIUM-POTASSIUM-EXCHANGING ATPASE; STEATORRHEA;

EID: 80053209593     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2011.05.005     Document Type: Article

References (123)

1. Chassany O., Michaux A., Bergmann J.F. Drug-induced diarrhoea. Drug Saf 2000, 22(1):53-72.
2. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis 1992, 15:573-581.
3. Schiller L.R., Sellin J.H. Diarrhea. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management 2010, 211-231. Saunders Elsevier, Philadelphia. M. Feldman, L.S. Friedman, L.J. Brandt (Eds.).
4. Ratnaike R.N., Jones T.E. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging 1998, 13:245-253.
5. Ehrenpreis E.D., Nogueras J.J., Botoman V.A., et al. Serum electrolyte abnormalities secondary to Fleet's Phospho-Soda colonoscopy prep. A review of three cases. Surg Endosc 1996, 10:1022-1024.
6. Fleischer N., Brown H., Graham D.Y., et al. Chronic laxative-induced hyperaldosteronism and hypokalemia simulating Bartter's syndrome. Ann Intern Med 1969, 70:791-798.
7. Ehrenpreis E.D., Wieland J.M., Cabral J., et al. Symptomatic hypocalcemia, hypomagnesemia, and hyperphosphatemia secondary to Fleet's phospho-soda colonoscopy preparation in a patient with a jejunoileal bypass. Dig Dis Sci 1997, 42(4):858-860.
8. Nataf C., Desmazures C., Giraudeaux V., et al. Laxative-induced intestinal protein loss in normal subjects. Gastroenterol Clin Biol 1981, 5:187-192.
9. Pahor M., Guralnik J.M., Chrischilles E.A., et al. Use of laxative medication in older persons and associations with low serum albumin. J Am Geriatr Soc 1994, 42:50-56.
10. Ehrenpreis E.D. Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther 2009, 29(11):1202-1211.
11. Parakkal D., Ehrenpreis E.D. Calcium phosphate nephropathy from colonoscopy preparations: effect of body weight. Am J Gastroenterol 2010, 105:705.
12. Pasricha P.J. Chapter 46. Treatment of Disorders of Bowel Motility and Water Flux Antiemetics; Agents Used in Biliary and Pancreatic Disease In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed., Accessed December, 2010. http://www.accessmedicine.com/content.aspx?aID=946551.
13. Souter W.A. Bolus obstruction of gut after use of hydrophilic colloid laxatives. Br Med J 1965, 1:166-168.
14. Elliot D., Glover G.R. Large bowel perforation due to excessive bran ingestion. Br J Clin Pract 1983, 37:32-33.
15. Suhonen R., Kantola I., Björksten F. Anaphylactic shock due to ingestion of psyllium laxative. Allergy 1983, 38:363-365.
16. Bergogne-Bérézin E. Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents 2000, 16:521-526.
17. Clausen M.R., Bonnén H., Tvede M., et al. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterology 1991, 101:1497-1504.
18. Roediger W.E. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980, 21:793-798.
19. Roediger W.E. The colonic epithelium in ulcerative colitis: an energy-deficiency disease?. Lancet 1980, 2:712-715.
20. Harig J.M., Soergel K.H., Komorowski R.A., et al. Treatment of diversion colitis with short-chain fatty acid irrigation. N Engl J Med 1989, 320:23-28.
21. Abraham B., Sellin J.H. Drug-induced diarrhea. Curr Gastroenterol Rep 2007, 9(5):365-372.
22. O'Brien J., Thompson D.G., Burnham W.R., et al. Beta blocking drugs accelerate the passage of carbohydrate to the colon. Gut 1986, 27:A629. [Abstract].
23. Sellin J.H. The pathophysiology of diarrhea. Clin Transpl 2001, 15:2-10.
24. Soffer E.E., Launspach J. Effect of misoprostol on postprandial intestinal motility and orocecal transit time in humans. Dig Dis Sci 1993, 38:851-855.
25. Mauricio A.C., Slawik M., Heitzmann D., et al. Deoxycholic acid (DOC) affects the transport properties of distal colon. Pflugers Arch 2000, 439(5):532-540.
26. Venkatasubramanian J., Selvaraj N., Carlos M., et al. Differences in Ca(2+) signaling underlie age-specific effects of secretagogues on colonic, vol Cl(-) transport. Am J Physiol Cell Physiol 2001, 280:C646-C658.
27. Högenauer C., Hammer H.F., Krejs G.J., et al. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998, 27:702-710.
28. Hofmann A.F. Bile acids, diarrhea, and antibiotics: Data, speculation, and a unifying hypothesis. J Infect Dis 1977, 135(Suppl):S126-S132.
29. McJunkin B., Fromm H., Sarva R.P., et al. Factors in the mechanism of diarrhea in bile acid malabsorption: fecal pH-a key determinant. Gastroenterology 1981, 80:1454-1464.
30. Binder H.J., Dobbins J.W., Whiting D.S. Evidence against importance of altered mucosal permeability in Ricinoleic acid induced fluid secretion. Gastroenterology 1977, 72:1029. [Abstract], A-6.
31. Ramakrishna B.S., Mathan M., Mathan V.I. Alteration of colonic absorption by long-chain unsaturated fatty acids. Influence of hydroxylation and degree of unsaturation. Scand J Gastroenterol 1994, 29:54-58.
32. Smith B. Effect of irritant purgatives on the myenteric plexus in man and the mouse. Gut 1968, 9:139-143.
33. Riemann J.F., Schmidt H. Ultrastructural changes in the gut autonomic nervous system following laxative abuse and in other conditions. Scand J Gastroenterol 1982, 71(Suppl):111-124.
34. Balázs M. Melanosis coli. Ultrastructural study of 45 patients. Dis Colon Rectum 1986, 29:839-844.
35. Riemann J.F., Schenk J., Ehler R., et al. Ultrastructural changes of colonic mucosa in patients with chronic laxative misuse. Acta Hepato Gastroenterol 1978, 25:213-218.
36. Dufour P., Gendre P. Ultrastructure of mouse intestinal mucosa and changes observed after long term anthraquinone administration. Gut 1984, 25:1358-1363.
37. Ghadially F.N., Parry E.W. An electron-microscope and histochemical study of melanosis coli. J Pathol Bacteriol 1966, 92:313-317.
38. Ghadially F.N., Walley V.M. Melanoses of the gastrointestinal tract. Histopathology 1994, 25:197-207.
39. Koskela E., Kulju T., Collan Y. Melanosis coli. Prevalence, distribution, and histologic features in 200 consecutive autopsies at Kuopio University Central Hospital. Dis Colon Rectum 1989, 32:235-239.
40. Walker N.I., Bennett R.E., Axelsen R.A. Melanosis coli. A consequence of anthraquinone-induced apoptosis of colonic epithelial cells. Am J Pathol 1988, 131:465-476.
41. Krbavcic A., Pecar S., Schara M., et al. Anthranoid free radicals found in Pseudomelanosis coli. Pharmazie 1998, 53:336-338.
42. Benavides S.H., Morgante P.E., Monserrat A.J., et al. The pigment of melanosis coli: A lectin histochemical study. Gastrointest Endosc 1997, 46:131-138.
43. Speare G.S. Melanosis coll; experimental observations on its production and elimination in twenty-three cases. Am J Surg 1951, 82:631-637.
44. Nusko G., Schneider B., Schneider I., et al. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut 2000, 46:651-655.
45. Dukas L., Willet W.C., Colditz G.A., et al. Prospective study of bowel movement, laxative use, and risk of colorectal cancer among women. Am J Epidemiol 2000, 151:958-964.
46. Joo J.S., Ehrenpreis E.D., Gonzalez L., et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: The cathartic colon revisited. J Clin Gastroenterol 1998, 26:283-286.
47. Solomon R., Cherny N.I. Constipation and diarrhea in patients with cancer. Cancer J 2006, 12:355-364.
48. Bartels E.M., Bliddal H., Schøndorff P.K., et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010, 18(3):289-296.
49. Johanson J.F., Drossman D.A., Panas R., et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008, 27(8):685-696.
50. Long C.J., Ehrenpreis E.D. Chapter 36. Medications, Toxins and the Colon. Diseases of the Colon 2007, Informa Healthcare USA, New York. S.D. Wexner, N. Stollman (Eds.).
51. - secretion in rabbit descending colonic epithelium. Arch Pharmacolog 2005, 371:492-499.
52. Ehrenfeld M., Levy M., Sharon P., et al. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (Familial Mediterranean fever). Dig Dis Sci 1982, 27(8):723-727.
53. Chawla A., Karl P.I., Reich R.N., et al. Effect of olsalazine on sodium-dependent bile acid transport in rat ileum. Dig Dis Sci 1995, 40:943-948.
54. Scheurlen C., Allgayer H., Kruis W., et al. Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?. Clin Invest 1993, 71:286-289.
55. Pamukcu R., Hanauer S.B., Change E.B. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison of sulfasalazine and 5-aminosalicylic acid. Gastroenterology 1988, 95:975-981.
56. Xu Y., Villalona-Calero M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002, 13:1841-1851.
57. Yang X., Hu Z., Chan S.Y., et al. Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr Med Chem 2005, 12:1343-1358.
58. Bengt G. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005, 28:417-433.
59. Thomas J., Karver S., Cooney G.A., et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008, 358(22):2332-2343.
60. Büchler M.W., Seiler C.M., Monson J.R., et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther 2008, 28(3):312-325.
61. Wegener M., Wedmann B., Langhoff T., et al. Effect of hyperthyroidism on the transit of a caloric solid-liquid meal through the stomach, the small intestine, and the colon in man. J Clin Endocrinol Metab 1992, 75:745-749.
62. Guédon C., Bruna T., Ducrotté P., et al. Severe diarrhea caused by Ticlid associated with disorders of small intestine motility. Gastroenterol Clin Biol 1989, 13:934-937.
63. Beaugerie L., Luboinski J., Brousse N., et al. Drug induced lymphocytic colitis. Gut 1994, 35:426-428.
64. Duncan H.D., Talbot I.C., Silk D.B. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol 1997, 9:819-820.
65. Yaziji N., Rassiat E., Michiels C., et al. Modopar-induced lymphocytic colitis. Ann Pathol 1996, 16:25.
66. Bouchet-Laneuw F., Deplaix P., Dumollard J.M., et al. Chronic diarrhea following ingestion of Tardyferon associated with lymphocytic colitis. Gastroenterol Clin Biol 1997, 21:83-84.
67. Anttila V.J., Valtonen M. Carbamazepine-induced eosinophilic colitis. Epilepsia 1992, 33:119-121.
68. Chagnon J.P., Cerf M. Simvastatin-induced protein-losing enteropathy. Am J Gastroenterol 1992, 87:257.
69. Bo-Linn G.W., Vendrell D.D., Lee E., et al. An evaluation of the significance of microscopic colitis in patients with chronic diarrhea. J Clin Invest 1985, 75:1559-1569.
70. Morgan G.J., Poland M., DeLapp R.E. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicamin the elderly. Am J Med 1993, 95(Suppl 2A):19-27.
71. Bjarnason I., Williams P., Smethurst P., et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986, 27:1292-1297.
72. Lee F.D. Importance of apoptosis in the histopathology of drug related lesions in the large intestine. J Clin Pathol 1993, 46:118-122.
73. Kwo P.Y., Tremaine W.J. Nonsteroidal anti-inflammatory drug-induced enteropathy: Case discussion and review of the literature. Mayo Clin Proc 1995, 70:55-61.
74. Bjarnason I., Prouse P., Smith T., et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987, II:711-714.
75. Hall R.I., Petty A.H., Cobden I., et al. Enteritis and colitis associated with mefenamic acid. Br Med J (Clin Res Ed) 1983, 287:1182.
76. Lapoile E., Bellaiche G., Nouts A., et al. Pseudomembranous colitis after ingestion of diclofenac. Gastroenterol Clin Biol 1988, 22:100-101.
77. Gentric A., Pennec Y.L. Diclofenac-induced pseudomembranous colitis. Lancet 1992, 340:126-127.
78. Jackson C.W., Haboubi N.Y., Whorwell P.J., et al. Gold induced enterocolitis. Gut 1986, 27:452-456.
79. Evron E., Brautbar C., Becker S., et al. Correlation between gold-induced enterocolitis and the presence of the HLA-DRB1*0404 allele. Arthritis Rheum 1995, 38:755-759.
80. Richardson G., Dobish R. Chemptherapy induced diarrhea. J Oncol Pharm Practice 2007, 13:181-198.
81. Milles S.S., Muggia A.L., Spiro H.M. Colonic histological changes induced by 5-fluorouracil. Gastroenterology 1962, 43:391.
82. Ikuno N., Soda H., Watanabe M., et al. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995, 87(24):1876-1883.
83. Kawato Y., Aonuma M., Hirota Y., et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991, 51(16):4187-4191.
84. Gupta E., Lestingi T.M., Mick R., et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994, 54(14):3723-3725.
85. Wasserman E., Myara A., Lokiec F., et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997, 8(10):1049-1051.
86. Jarvis B., Shevchuk Y.M. Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. Pharmacotherapy 1997, 17:606-611.
87. Husain A., Aptaker L., Spriggs D.R., et al. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998, 71:104-107.
88. Biggar W.D., Crawford L., Cardella C., et al. Malakoplakia and immunosuppressive therapy. Reversal of clinical and leukocyte abnormalities after withdrawal of prednisone and azathioprine. Am J Pathol 1985, 119:5-11.
89. Mazzoleni G., de Sa D., Gately J., et al. Yersinia enterocolitica infection with ileal perforation associated with iron overload and deferoxamine therapy. Dig Dis Sci 1991, 36:1154-1160.
90. Olm M., Gonzalez F.J., Garcia-Valdecasas J.C., et al. Necrotising colitis with perforation in diarrhoic patients treated with loperamide. Eur J Clin Pharmacol 1991, 40:415-416.
91. Pat J.R., Jayakumar S., Driman D.K. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol 2008, 32:1367-1372.
92. Benson A.B., Ajani J.A., Catalano R.B., et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004, 22:2918-2926.
93. Al-Dasooqi N., Gibson R., Bowen J., et al. HER2 targeted therapies for cancer and the gastrointestinal tract. Curr Drug Targets 2009, 10:537-542.
94. Chow J.Y., Carlstrom K., Barrett K.E. Growth hormone reduces chloride secretion in human colonic epithelial cells via EGF receptor and extracellular regulated kinase. Gastroenterology 2003, 125:1114-1124.
95. Peters M., Balfour J., Arnold D. Review article: Panitumumab-a fully human anti-EGFR monoclonal antibody for the treatment of metastatic colorectal cancer. Aliment Pharmacol Ther 2008, 28:269-281.
96. Kane R.C., Bross P.F., Farrell A.T., et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8(6):508-513.
97. Mann B.S., Johnson J.R., Cohen M.H., et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12(10):1247-1252.
98. Martin P., Manley P.N., Depew W.T., et al. Isotretinoin-associated proctosigmoiditis. Gastroenterology 1987, 93:606-609.
99. Reddy D., Siegel C.A., Sands B.E., et al. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol 2006, 101(7):1569-1573.
100. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. N Engl J Med 1994, 330:257-262.
101. Periti P., Mazzci T., Mini E., et al. Adverse effects of macrolide antibacterials. Drug Saf 1993, 9:346-364.
102. Maignan M., Schuhmacher H., Pierfitte C., et al. Pseudomembranous colitis associated with josamycin. Therapie 1994, 49:461-462.
103. Bauwens J.E., McFarland L.V., Melcher S.A. Recurrent Clostridium difficile disease following ciprofloxacin use. Ann Pharmacother 1997, 31:1090.
104. Pothoulakis C. Pathogenesis of Clostridium difficile-associated diarrhoea. Eur J Gastroenterol Hepatol 1996, 8:1041-1047.
105. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353(23):2442-2449.
106. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359:1932-1940.
107. Modi N., Wilcox M.H. Evidence for antibiotic induced Clostridium perfringens diarrhoea. J Clin Pathol 2001, 54:748-751.
108. Boyce J.M., Havill N.L. Nosocomial antibiotic-associated diarrhea associated with enterotoxin-producing strains of methicillin-resistant Staphylococcus aureus. Am J Gastroenterol 2005, 100:1828-1834.
109. Gupta T.P., Ehrinpreis M.N. Candida-associated diarrhea in hospitalized patients. Gastroenterology 1990, 98(3):780-785.
110. Högenauer C., Langner C., Beubler E., et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006, 355(23):2418-2426.
111. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294(23):2989-2995.
112. Poles M.A., Fuerst M., McGowan I., et al. HIV-related diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART. Am J Gastroenterol 2001, 96(6):1831-1837.
113. Pike I.M., Nicaise C. The didanosine expanded access program: safety analysis. Clin Infect Dis 1993, 16(Suppl 1):63-68.
114. Kessler H.A., Johnson J., Follansbee S., et al. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1. Clin Infect Dis 2002, 34:535-542.
115. Sherman D.S., Fish D.N. Management of protease inhibitor-associated diarrhea. Clin Infect Dis 2000, 30:908-914.
116. Cocohoba J., Raltegravir D.B.J. The first HIV integrase inhibitor. Clin Ther 2008, 30(10):1747-1765.
117. Sjöström L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352(9123):167-172.
118. Longstreth G.F., Newcomer A.D. Drug-induced malabsorption. Mayo Clin Proc 1975, 50:284-293.
119. Dobbins W.O., Herrero B.A., Mansbach C.M. Morphologic alterations associated with neomycin induced malabsorption. Am J Med Sci 1968, 255:63-67.
120. Knodel L.C., Talbert R.L. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987, 2:10-32.
121. Berchtold P., Dahlqvist A., Gustafson A., et al. Effects of a biguanide (Metformin) on vitamin B 12 and folic acid absorption and intestinal enzyme activities. Scand J Gastroenterol 1971, 6(8):751-754.
122. Nakamura T., Kudoh K., Takebe K., et al. Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects. Intern Med 1994, 33:593-596.
123. Kuhn J.M., Legrand A., Ruiz J.M., et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994, 38:213-219.